Get started
Author

Cristina Rodríguez

Observed names: C Rodriguez, C Rodríguez, C. Rodríguez, CRISTINA RODRÍGUEZ, Cristina Rodriguez, Cristina Rodríguez‐Gutiérrez, Rodriguez, Cristina, Rodríguez, Cristina
Observed institutions: Hospital de Sant Pau, Bellvitge University Hospital, Complejo Hospitalario de Navarra, Navarre Institute of Health Research, Hospital Clínic de Barcelona, Mútua Terrassa, Hospital Universitario de La Princesa, Hospital Del Mar, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital de Cruces, Hospital Universitari Germans Trias i Pujol, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Pharmacoeconomics and Health Outcomes Research Iberia (Spain), Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Universitat de Barcelona, Universidad de Navarra
ORCID: 0000-0003-3954-0736
Observed ORCID: 0000-0003-3954-0736
OpenAlex ID: A5100780964
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
2018 · M Chaparro, A Verreth, et al. · The American Journal of Gastroenterology · 171
PDF
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
2016 · M J Casanova, M Chaparro, et al. · The American Journal of Gastroenterology · 114
PDF
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry
2020 · María Chaparro, Ana Garre, et al. · Journal of Crohn s and Colitis · 107
PDF
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
2021 · María Chaparro, Ana Garre, et al. · Journal of Clinical Medicine · 106
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry
2021 · María Chaparro, Ana Garre, et al. · Journal of Crohn s and Colitis · 84
PDF
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
2017 · Carlos Taxonera, Cristina Rodríguez, et al. · Inflammatory Bowel Diseases · 80
PDF
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry
2019 · María José Casanova, María Chaparro, et al. · Inflammatory Bowel Diseases · 54
PDF
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study
2019 · Ivan Guerra, Luis Bujanda, et al. · Journal of Crohn s and Colitis · 54
Post-Operative Morbidity and Mortality of a Cohort of Steroid Refractory Acute Severe Ulcerative Colitis: Nationwide Multicenter Study of the GETECCU ENEIDA Registry
2018 · I Ordás, E Domènech, et al. · The American Journal of Gastroenterology · 40
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
2022 · María Chaparro, Diana Acosta, et al. · The American Journal of Gastroenterology · 36
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU
2022 · Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, et al. · The American Journal of Gastroenterology · 24
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
2019 · María Chaparro, Manuel Barreiro-de Acosta, et al. · Therapeutic Advances in Gastroenterology · 24
Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain
2022 · Xavier Calvet, Julián Panés, et al. · Journal of Crohn s and Colitis · 22
PDF
Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study
2023 · María José Casanova, Óscar Nantes, et al. · Alimentary Pharmacology & Therapeutics · 20
Clinical features, therapeutic requirements and evolution of patients with Crohn’s disease and upper gastrointestinal involvement (CROHNEX study)
2021 · Empar Sainz, Yamile Zabana, et al. · Alimentary Pharmacology & Therapeutics · 20
Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors
2018 · Carmen Muñoz-Villafranca, Jone Ortiz de Zarate, et al. · Digestive and Liver Disease · 16
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
2021 · Margalida Calafat, Míriam Mañosa, et al. · Journal of Crohn s and Colitis · 14
Effectiveness and safety of methotrexate monotherapy in patients with Crohn’s disease refractory to anti‐TNF‐α: results from the ENEIDA registry
2021 · Francisco Mesonero, Jesús Castro‐Poceiro, et al. · Alimentary Pharmacology & Therapeutics · 12
PDF
Does capsule endoscopy impact clinical management in established Crohn's disease?
2021 · Alfonso Elosua, María Rullan, et al. · Digestive and Liver Disease · 11
Upadacitinib Maintenance Therapy in Crohn’s Disease: Final Results From the Randomized Phase 3 U-ENDURE Study
2025 · Remo Panaccione, Miguel Regueiro, et al. · Clinical Gastroenterology and Hepatology · 9
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
2022 · Ana Gutiérrez, Pedro Zapater, et al. · Frontiers in Medicine · 9
P790 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU
2019 · M Chaparro, M Barreiro-de Acosta, et al. · Journal of Crohn s and Colitis · 8
Management and Long-term Outcomes of Crohn’s Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
2022 · Manuel Barreiro-de Acosta, Sabino Riestra, et al. · Journal of Crohn s and Colitis · 7
Tasas de colectomía en colitis ulcerosa 15 años después del diagnóstico. Datos de la cohorte Navarra 2001-2003
2021 · Cristina Rodríguez, Alfonso Elosua, et al. · Gastroenterología y Hepatología · 6
P744 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU
2020 · M Chaparro, M Barreiro-de Acosta, et al. · Journal of Crohn s and Colitis · 6
PDF
Works count: 70
Citation count: 1,136
H-index: 17
I10-index: 21
Year
Topic
Type